Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

NCT00378508 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: mAb hOKT3gamma1(Ala-Ala), Teplizumab
DRUG: Placebo Arm

Sponsor

Yale University

Collaborators

[object Object]
[object Object]